CLINICAL_TRIALS
trial_result
· 2010-02-22
Clinical Trial Update: Study of XL999 in Patients With Acute Myeloid Leukemia (AML) [Phase 2]
Summary
A Phase 2 trial of XL999 in acute myeloid leukemia has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Symphony Evolution, Inc. | Conditions: Acute Myeloid Leukemia, AML | Phase 2 | Status: TERMINATED